Target sites for the design of anti-trypanosomatid drugs based on the structure of dihydroorotate dehydrogenase

Current Pharmaceutical Design

Volumn 19, Issue 14, 2013, Pages 2615-2627

  Pinheiro, Matheus Pinto ^a   da Silva Emery, Flávio ^a   Cristina Nonato, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dihydroorotate dehydrogenase; Leishmania major; Sites for drug discovery; Trypanosoma brucei; Trypanosoma cruzi; Trypanosomatids

Indexed keywords

ALPHA RESORCYLIC ACID; ANTITRYPANOSOMAL AGENT; DIHYDROOROTATE DEHYDROGENASE; ISOTHIOCYANIC ACID DERIVATIVE; PHENYL ISOTHIOCYANATE; PYRIMIDINE DERIVATIVE; PYRIMIDINE NUCLEOTIDE;

AFRICAN TRYPANOSOMIASIS; BINDING SITE; CHAGAS DISEASE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME SPECIFICITY; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; HOST PARASITE INTERACTION; ISOTHERMAL TITRATION CALORIMETRY; KINETOPLASTIDA; LEISHMANIA MAJOR; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; REVIEW; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

AMINO ACID SEQUENCE; ANIMALS; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PROTEIN CONFORMATION; PYRIMIDINE NUCLEOTIDES; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA; TRYPANOSOMIASIS;

EID: 84877804038     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319140011     Document Type: Review

References (89)

1. McGhee RB, Cosgrove WB. Biology And Physiology Of The Lower Trypanosomatidae. Microbiological Rev 1980; 44: 140-73.
2. Stuart K, Brun R, Croft S, et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clinical Investigation 2008; 118: 1301-1310.
3. Teixeira SM, Cardoso de Paiva RM, Kangussu-Marcolino MM, DaRocha WD. Trypanosomatid comparative genomics: Contributions to the study of parasite biology and different parasitic diseases. Genetics Mol Biol 2012; 35: 1-17.
4. Clayton J. Chagas disease 101. Nature 2010; 465: S4-5.
5. Petherick A. Country by country. Nature 2010; 465: S10-11.
6. Coura JR, Vinas PA. Chagas disease: a new worldwide challenge. Nature 2010; 465: S6-7
7. Geiger A, Simo G, Grebaut P, Peltier JB, Cuny G, Holzmuller P. Transcriptomics and proteomics in human African trypanosomiasis: Current status and perspectives. J Proteomics 2011; 74: 1625-43.
8. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 2010; 375: 148-59.
9. Kobets T, Grekov I, Lipoldova M. Leishmaniasis: Prevention, Parasite Detection and Treatment. Curr Med Chem 2012; 19: 1443-74.
10. Desjeux P. Leishmaniasis: current situation and new perspectives. Comparative Immunology Microbiology and Infectious Diseases 2004; 27: 305-18.
11. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infectious Diseases 2007; 7: 581-96.
12. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
13. Conteh L, Engels T, Molyneux DH. Neglected Tropical Diseases 4 Socioeconomic aspects of neglected tropical diseases. Lancet 2010; 375: 239-47.
14. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing Drug Innovation for Neglected Diseases-Criteria for Lead Progression. Plos Neglected Tropical Diseases 2009; 3.
15. Jakobsen PH, Wang M-W, Nwaka S. Innovative Partnerships for Drug Discovery against Neglected Diseases. Plos Neglected Tropical Diseases 2011; 5.
16. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2006; 2: 701-10.
17. Nwaka S, Ridley RG. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nature Reviews Drug Discovery 2003; 2: 919-928.
18. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clinical Microbiol Rev 2006; 19: 111-+.
19. D'Silva C. Human African trypanosomiasis: future prospects for chemotherapy. Drugs of the Future 2007; 32: 149-60.
20. Alsford S, Eckert S, Baker N, et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 2012; 482: 232-U125.
21. Herwaldt BL. Leishmaniasis. Lancet 1999; 354: 1191-9.
22. Coura JR, Borges-Pereira J. Chagas disease. What is known and what should be improved: a systemic review. Revista Da Sociedade Brasileira De Medicina Tropical 2012; 45: 286-96.
23. Molina J, Martins-Filho OA, Brener Z, Romanha AJ, Loebenberg D, Urbina JA. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrobial Agents Chemotherap 2000; 44: 150-5.
24. Berriman M, Ghedin E, Hertz-Fowler C, et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309: 416-22.
25. El-Sayed NM, Myler PJ, Bartholomeu DC, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005; 309: 409-15.
26. Ivens AC, Peacock CS, Worthey EA, et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005; 309: 436-42.
27. Peacock CS, Seeger K, Harris D, et al. Comparative genomic analysis of three Leishmania species that cause diverse human disease. Nature Genetics 2007; 39: 839-47.
28. El-Sayed NM, Myler PJ, Blandin G, et al. Comparative genomics of trypanosomatid parasitic protozoa. Science 2005; 309: 404-9.
29. Carter NS, Yates P, Arendt CS, Boitz JM, Ullman B. Purine and pyrimidine metabolism in Leishmania. Drug Targets Kinetoplastid Parasites 2008; 625: 141-54.
30. Michels PAM, Bringaud F, Herman M, Hannaert V. Metabolic functions of glycosornes in trypanosomatids. Biochimica Et Biophysica Acta-Mol Cell Res 2006; 1763: 1463-77.
31. Opperdoes FR, Szikora JP. In silico prediction of the glycosomal enzymes of Leishmania major and trypanosomes. Mol Biochem Parasitol 2006; 147: 193-206.
32. Ceron CR, Dearaujocaldas R, Felix CR, Mundim MH, Roitman I. Purine metabolism in trypanosomatids. J Protozool 1979; 26: 479-83.
33. Jones ME. Pyrimidine nucleotide biosynthesis in animals-genes, enzymes, and regulation of ump biosynthesis. Ann Rev Biochem 1980; 49: 253-79.
34. Gao GH, Nara T, Nakajima-Shimada J, Aoki T. Novel organization and sequences of five genes encoding all six enzymes for de novo pyrimidine biosynthesis in Trypanosoma cruzi. J Mol Biol 1999; 285: 149-61.
35. Wilson ZN, Gilroy CA, Boitz JM, Ullman B, Yates PA. Genetic Dissection of Pyrimidine Biosynthesis and Salvage in Leishmania donovani. J Biol Chem 2012; 287: 12759-70.
36. Hashimoto M, Morales J, Fukai Y, et al. Critical importance of the de novo pyrimidine biosynthesis pathway for Trypanosoma cruzi growth in the mammalian host cell cytoplasm. Biochem Biophys Res Communications 2012; 417: 1002-6.
37. Gutteridge WE, Gaborak M. Re-Examination Of Purine And Pyrimidine Synthesis In The 3 Main Forms Of Trypanosoma-Cruzi. Int J Biochem 1979; 10: 415-22.
38. Traut TW. Physiological Concentrations Of Purines And Pyrimidines. Mol Cellular Biochem 1994; 140: 1-22.
39. Vyas VK, Ghate M. Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors. Mini-Rev Med Chem 2011; 11: 1039-55.
40. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47: 273-89.
41. Baumann P, Mandl-Weber S, Voelkl A, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Therapeut 2009; 8: 366-75.
42. Boyd AS. Leflunomide in dermatology. J Am Acad Dermatol 2012; 66: 673-9.
43. Marcinkeviciene J, Rogers MJ, Kopcho L, et al. Selective inhibition of bacterial dihydroorotate dehydrogenases by thiadiazolidinediones. Biochem Pharmacol 2000; 60: 339-42.
44. Haque TS, Tadesse S, Marcinkeviciene J, et al. Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase. J Med Chem 2002; 45: 4669-78.
45. Copeland RA, Marcinkeviciene J, Haque TS, et al. Helicobacter pylori-selective antibacterials based on inhibition of pyrimidine biosynthesis. J Biological Chem 2000; 275: 33373-8.
46. Booker ML, Bastos CM, Kramer ML, et al. Novel Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in the Mouse Model. J Biological Chem 2010; 285: 33054-64.
47. Patel V, Booker M, Kramer M, et al. Identification and Characterization of Small Molecule Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase. J Biological Chem 2008; 283: 35078-85.
48. Arakaki TL, Buckner FS, Gillespie JR, et al. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol 2008; 68: 37-50.
49. Takashima E, Inaoka DK, Osanai A, et al. Characterization of the dihydroorotate dehydrogenase as a soluble fumarate reductase in Trypanosoma cruzi. Mol Biochem Parasitol 2002; 122: 189-200.
50. Bjornberg O, Jordan DB, Palfey BA, Jensen KF. Dihydrooxonate is a substrate of dihydroorotate dehydrogenase (DHOD) providing evidence for involvement of cysteine and serine residues in base catalysis. Archives Biochem Biophys 2001; 391: 286-94.
51. Feliciano PR, Cordeiro AT, Costa AJ, Nonato MC. Cloning, expression, purification, and characterization of Leishmania major dihydroorotate dehydrogenase. Protein Expression Purificat 2006; 48: 98-103.
52. Norager S, Jensen KF, Bjornberg O, Larsen S. E-coli dihydroorotate dehydrogenase reveals structural and functional distinctions between different classes of dihydroorotate dehydrogenases. Structure 2002; 10: 1211-23.
53. Liu SP, Neidhardt EA, Grossman TH, Ocain T, Clardy J. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure with Folding Des 2000; 8: 25-33.
54. Hurt DE, Widom J, Clardy J. Structure of Plasmodium falciparum dihydroorotate dehydrogenase with a bound inhibitor. Acta Crystallographica Section D-Biological Crystallography 2006; 62: 312-23.
55. Bjornberg O, Gruner AC, Roepstorff P, Jensen KF. The activity of Escherichia coli dihydroorotate dehydrogenase is dependent on a conserved loop identified by sequence homology, mutagenesis, and limited proteolysis. Biochemistry 1999; 38: 2899-908.
56. Rowland P, Nielsen FS, Jensen KF, Larsen S. The crystal structure of the flavin containing enzyme dihydroorotate dehydrogenase A from Lactococcus lactis. Structure 1997; 5: 239-52.
57. Cordeiro AT, Feliciano PR, Pinheiro MP, Nonato MC. Crystal structure of dihydroorotate dehydrogenase from Leishmania major. Biochimie.
58. Liu Y, Gao ZQ, Liu CP, et al. Structure of the putative dihydroorotate dehydrogenase from Streptococcus mutans. Acta Crystallographica Section F-Structural Biol Crystallization Communications 2011; 67: 182-7.
59. Shi J, Dertouzos J, Gafni A, Steel D, Palfey BA. Single-molecule kinetics reveals signatures of half-sites reactivity in dihydroorotate dehydrogenase A catalysis. Proc Natl Acad Sci USA 2006; 103: 5775-80.
60. Nielsen FS, Andersen PS, Jensen KF. The B form of dihydroorotate dehydrogenase from Lactococcus lactis consists of two different subunits, encoded by the pyrDb and pyrK genes, and contains FMN, FAD, and FeS redox centers. J Biological Chem 1996; 271: 29359-65.
61. Marcinkeviciene J, Tinney LM, Wang KH, Rogers MJ, Copeland RA. Dihydroorotate dehydrogenase B of Enterococcus faecalis. Characterization and insights into chemical mechanism. Biochemistry 1999; 38: 13129-37.
62. Kahler AE, Nielsen FS, Switzer RL. Biochemical characterization of the heteromeric Bacillus subtilis dihydroorotate dehydrogenase and its isolated subunits. Archives of Biochemistry and Biophysics 1999; 371: 191-201.
63. Argyrou A, Washabaugh MW, Pickart CM. Dihydroorotate dehydrogenase from Clostridium oroticum is a class 1B enzyme and utilizes a concerted mechansim of catalysis. Biochemistry 2000; 39: 10373-84.
64. Rowland P, Norager S, Jensen KF, Larsen S. Structure of dihydroorotate dehydrogenase B: Electron transfer between two flavin groups bridged by an iron-sulphur cluster. Structure 2000; 8: 1227-38.
65. Cordeiro AT, Feliciano PR, Nonato MC. Crystallization and preliminary X-ray diffraction analysis of Leishmania major dihydroorotate dehydrogenase. Acta Crystallographica Section FStructural Biology and Crystallization Communications 2006; 62: 1049-51.
66. Hansen M, Le Nours J, Johansson E, et al. Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci 2004; 13: 1031-42.
67. Arakaki TL, Buckner FS, Gillespie JR, et al. Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol 2008; 68: 37-50.
68. Pinheiro MP, Iulek J, Nonato MC. Crystal structure of Trypanosoma cruzi dihydroorotate dehydrogenase from Y strain. Biochem Biophys Res Communications 2008; 369: 812-7.
69. Inaoka DK, Sakamoto K, Shimizu H, et al. Structures of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with substrates and products: Atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction. Biochemistry 2008; 47: 10881-91.
70. Bjornberg O, Rowland P, Larsen S, Jensen KF. Active site of dihydroorotate dehydrogenase A from Lactococcus lactis investigated by chemical modification and mutagenesis. Biochemistry 1997; 36: 16197-205.
71. Fagan RL, Jensen KF, Bjornberg O, Palfey BA. Mechanism of flavin reduction in the class 1A dihydroorotate dehydrogenase from Lactococcus lactis. Biochemistry 2007; 46: 4028-36.
72. Marcinkeviciene J, Jiang WJ, Locke G, Kopcho LM, Rogers MJ, Copeland RA. A second dihydroorotate dehydrogenase (type A) of the human pathogen Enterococcus faecalis: Expression, purification, and steady-state kinetic mechanism. Archives of Biochem Biophys 2000; 377: 178-86.
73. Norager S, Arent S, Bjornberg O, et al. Lactococcus lactis dihydroorotate dehydrogenase A mutants reveal important facets of the enzymatic function. J Biological Chem 2003; 278: 28812-22.
74. Rowland P, Bjornberg O, Nielsen FS, Jensen KF, Larsen S. The crystal structure of Lactococcus lactis dihydroorotate dehydrogenase A complexed with the enzyme reaction product throws light on its enzymatic function. Protein Sci 1998; 7: 1269-79.
75. McDonald CA, Palfey BA. Substrate Binding and Reactivity Are Not Linked: Grafting a Proton-Transfer Network into a Class 1A Dihydroorotate Dehydrogenase. Biochem 2011; 50: 2714-6.
76. Defrees SA, Sawick DP, Cunningham B, Heinstein PF, Morre DJ, Cassady JM. Structure Activity Relationships Of Pyrimidines As Dihydroorotate Dehydrogenase Inhibitors. Biochem Pharmacol 1988; 37: 3807-16.
77. Hurt DE, Sutton AE, Clardy J. Brequinar derivatives and speciesspecific drug design for dihydroorotate dehydrogenase. Bioorganic Med Chem Letters 2006; 16: 1610-5.
78. Palfey BA, Bjornberg O, Jensen F. Specific inhibition of a family 1A dihydroorotate dehydrogenase by benzoate pyrimidine analogues. J Med Chem 2001; 44: 2861-4.
79. Wolfe AE, Thymark M, Gattis SG, et al. Interaction of benzoate pyrimidine analogues with class 1A dihydroorotate dehydrogenase from Lactococcus lactis. Biochemistry 2007; 46: 5741-53.
80. Cheleski J, Rocha JR, Pinheiro MP, et al. Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery. Eur J Med Chem 2010; 45: 5899-909.
81. Couto SG, Nonato MC, Costa-Filho AJ. Defects in vesicle core induced by Escherichia coli dihydroorotate dehydrogenase. Biophysical J 2008; 94: 1746-53.
82. Couto SG, Cristina Nonato M, Costa-Filho AJ. Site directed spin labeling studies of Escherichia coli dihydroorotate dehydrogenase N-terminal extension. Biochem Biophys Res Communications 2011; 414: 487-92.
83. Ottosen MB, Bjornberg O, Norager S, Larsen S, Palfey BA, Jensen KF. The dimeric dihydroorotate dehydrogenase A from Lactococcus lactis dissociates reversibly into inactive monomers. Protein Sci 2002; 11: 2575-83.
84. Wilderspin AF, Green NM. The Reaction Of Fluorescein Isothiocyanate With Thiols-A Method For Assay Of Isothiocyanates. Analytical Biochem 1983; 132: 449-55.
85. Edman P. Method For Determination Of The Amino Acid Sequence In Peptides. Acta Chemica Scandinavica 1950; 4: 283-93.
86. Mi L, Di Pasqua AJ, Chung FL. Proteins as binding targets of isothiocyanates in cancer prevention. Carcinogenesis 2011; 32: 1405-13.
87. Brown KK, Hampton MB. Biological targets of isothiocyanates. Biochimica Et Biophysica Acta-General Subjects 2011; 1810: 888-94.
88. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010; 66: 486-501.
89. Gouet P, Courcelle E, Stuart DI, Metoz F. ESPript: analysis of multiple sequence alignments in PostScript. Bioinformatics 1999; 15: 305-8.